e-learning
resources
Breathe
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness
Daisy J.A. Janssen, Marieke H.J. van den Beuken-van Everdingen, Cornelia A. Verberkt, Jacques P.H.M. Creemers, Emiel F.M. Wouters
Source:
Breathe, 15 (3) e122; 10.1183/20734735.0183-2019
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Daisy J.A. Janssen, Marieke H.J. van den Beuken-van Everdingen, Cornelia A. Verberkt, Jacques P.H.M. Creemers, Emiel F.M. Wouters. Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness. Breathe, 15 (3) e122; 10.1183/20734735.0183-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness
Source: Eur Respir J, 49 (5) 1601858; 10.1183/13993003.01858-2016
Year: 2017
Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
The prevelance of chronic nasal symptoms in COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 264s
Year: 2002
Overdiagnosis of COPD and asthma among elderly with chronic dyspnea
Source: Virtual Congress 2021 – Primary care diagnosis and multimorbidities
Year: 2021
Efficacy of inhalation from different powder inhalators in COPD patiens with chronic respiratory failure
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006
High-flow nasal cannulae therapy or NIV in patients with exacerbations of chronic obstructive pulmonary disease?
Source: Sleep and Breathing Conference 2021
Year: 2021
Montelukast and budesonide therapy of asthmatic patients suffering from chronic cough
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD
Source: Eur Respir J 2013; 41: 993-995
Year: 2013
Dyspnea and hypoxemia in COPD and CHF patients is more severe and prolonged after acetate hemodialysis
Source: Annual Congress 2008 - Exercise: system responses
Year: 2008
The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease)
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Chronic cough in COPD
Source: Annual Congress 2003 - New pathophysiological aspects in COPD
Year: 2003
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history
Source: Eur Respir J 2011; 38: 553-560
Year: 2011
Real-life experience of older patients requiring NIV for exacerbations of chronic obstructive pulmonary disease
Source: Annual Congress 2009 - New trends in noninvasive ventilation for acute respiratory failure
Year: 2009
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Sertraline effects on dyspnea in patients with severe COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 288s
Year: 2005
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
frequent exacerbations of COPD are associated with severity of airflow limitation and chronic cough, sputum production.
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Effect of erdosteine on airflow obstruction and symptom recovery in severe COPD exacerbations
Source: Annual Congress 2011 - COPD management
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept